Overview
- Intuitive reported stronger Q2 operations with 468 da Vinci systems sold, a global installed base of 11,710 systems, and a 16% year‑over‑year rise in procedures.
- Medtronic and Johnson & Johnson have secured U.S. approvals for their surgical‑robot systems, but those clearances apply to selected procedures rather than broad use.
- Investors remain cautious despite the operational gains because the stock has fallen roughly 40% from its early‑2025 high and still trades at a high price‑to‑earnings ratio.
- The company’s revenue model relies on recurring instruments and service sales tied to an expanding installed base, and management sees an upgrade cycle and extended‑use instrument programs as drivers of future revenue.
- Key risks to monitor include competitors winning broader procedure authorizations, supply and tariff pressures on margins, and hospital decisions about replacing or adding platforms that will shape competition over time.